Navigation Links
NanoVibronix Receives FDA Clearance for its PainShield(TM) MD Device

Portable Solution for Effective Localized Pain Management

NESHER, Israel, October 23 /PRNewswire/ -- NanoVibronix, a medical device company, announced that the US Food and Drug Administration (FDA) has granted 510K clearance to market PainShield(TM) MD, a diathermy device used to treat pain. PainShield is the first hands-free, patch-based diathermy device, thus allowing for an entirely new dimension in ultrasound treatment of pain and soft tissue healing. The PainShield consists of a disposable patch connected to a portable reusable driver and generates ultrasound waves to the desired area of the body.

(Photo: )

NanoVibronix President and CEO, Dr. Harold Jacob, stated, "PainShield MD, which implements our unique low frequency, low intensity ultrasound platform, is the first product from our pipeline to be cleared for marketing in the USA and represents a major milestone for NanoVibronix. NanoVibronix has created a platform that changes the way pain, the most common medical complaint, is managed. Our simple-to-use, portable device can treat pain locally including tendonitis, other musculoskeletal disorders, and post operative pain."

Dr. HM Adahan, Head of Pain Rehabilitation Center at Tel Hashomer Hospital, Israel, commented, "The PainShield appears to present a simple, elegant, economical, and effective solution to many of the most painful and common ailments that I treat. It also encourages patient independence and reduces the costs of therapy by promoting clinician supervised home based care."

Dr. Jonathan Rosenblum, Director, Diabetic Foot Service; Shaarei Zedek Medical Center, Jerusalem, Israel said, "My experience with PainShield MD has shown that it is highly effective in treating painful foot disorders including heel spur syndrome, tendon disease and wound pain." Dr. Rosenblum added "I am currently performing a clinical trial evaluating the effectiveness of PainShield on patients suffering from diabetic foot ulcers and initial results are very promising." "PainShield MD addresses many of the shortcomings of traditional therapeutic ultrasound and various other therapeutic modalities."

About the Company

NanoVibronix, located in Nesher Israel, develops products that implement its proprietary surface ultrasound technology. The company has also developed a unique line of catheter based disposable ultrasound devices designed to treat catheter-associated injury including pain, discomfort and biofilm formation. The first two products in this category are the UroShield(TM) for in-dwelling urinary catheters and NG-Shield(TM) for in-dwelling Nasogastric tubes.

For more information, please contact:

Amir Rippel, VP Marketing

NanoVibronix Ltd.

Tel: +972-4-820-0581

Fax: +972-4-820-2794

SOURCE NanoVibronix Ltd.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. PAREXEL Corporate Vice President Dr. Alberto Grignolo Receives Lifetime Achievement Award From Good Clinical Practice Journal
2. Medivation Receives Corporate Achievement Award From Huntingtons Disease Society of America
3. Bolder BioTechnology Receives $1.6 million NIH Grant to Continue Development of Multiple Sclerosis Drug
4. BIO Ventures for Global Health Receives $7 Million Grant from Gates Foundation to Engage Biotechnology in the Fight Against Neglected Diseases of the Developing World
5. Althea Technologies Receives Fast Growth Honors: Deloitte Technology Fast 50 and San Diego Business Journal Fast 100 Awards for the Fifth Consecutive Year
6. POET Receives Additional $76 Million in Federal Funding For Commercialization of Cellulosic Ethanol
7. Imaging Diagnostic Systems Receives its First Order for its CT Laser Mammography System for Israel
8. BioMS Medicals relapsing-remitting multiple sclerosis trial receives positive review from Data Safety Monitoring Board
9. deCODE Receives Nasdaq Deficiency Notice Relating to Market Value
10. Botaneco receives natural ingredient approval from ECOCERT(R) for Hydresia(TM) G2
11. Monogram Receives NASDAQ Notification
Post Your Comments:
(Date:6/27/2016)... ... June 27, 2016 , ... Parallel 6 , the ... today the Clinical Reach Virtual Patient Encounter CONSULT module which enables both ... physician and clinical trial team. , Using the CONSULT module, patients and physicians can ...
(Date:6/27/2016)... 27, 2016  Liquid Biotech USA ... of a Sponsored Research Agreement with The University ... (CTCs) from cancer patients.  The funding will be ... correlate with clinical outcomes in cancer patients undergoing ... then be employed to support the design of ...
(Date:6/24/2016)... , June 24, 2016 Epic Sciences ... detects cancers susceptible to PARP inhibitors by targeting ... cells (CTCs). The new test has already been ... in multiple cancer types. Over 230 ... damage response pathways, including PARP, ATM, ATR, DNA-PK ...
(Date:6/23/2016)... ... 23, 2016 , ... Mosio, a leader in clinical research ... Recruitment and Retention Tips.” Partnering with experienced clinical research professionals, Mosio revisits the ... tools, and strategies for clinical researchers. , “The landscape of how patients receive ...
Breaking Biology Technology:
(Date:6/20/2016)... Securus Technologies, a leading provider of ... safety, investigation, corrections and monitoring announced that after ... secured the final acceptance by all three (3) ... Systems (MAS) installed. Furthermore, Securus will have contracts ... by October, 2016. MAS distinguishes between legitimate wireless ...
(Date:6/7/2016)... 7, 2016  Syngrafii Inc. and San Antonio ... that includes integrating Syngrafii,s patented LongPen™ eSignature "Wet" ... collaboration will result in greater convenience for SACU ... while maintaining existing document workflow and compliance requirements. ... Highlights: ...
(Date:6/1/2016)... -- Favorable Government Initiatives Coupled With Implementation ... to Boost Global Biometrics System Market Through 2021  ... " Global Biometrics Market By Type, By End ... - 2021", the global biometrics market is projected to ... growing security concerns across various end use sectors such ...
Breaking Biology News(10 mins):